VYNE Company Profile and Key Details

Q: Who are the executives of VYNE?

Dr. Iain A. Stuart Ph.D.Chief Scientific OfficerMr. David SchuzSenior Vice President of Intellectual PropertyMr. Tyler ZerondaChief Financial Officer & TreasurerDr. Darrell S. Rigel M.S., M.D., MSConsultantMs. Mutya Harsch J.D.Gen. Counsel, Chief Legal Officer & Company Sec.Dr. Russell Elliott D.Phil.Senior Vice President of Pharmaceutical Devel.Mr. David T. DomzalskiChief Executive Officer, Pres & Director

NASDAQ : VYNE

VYNE Therapeutics

$0.64

0.0008+0.13%

At Close 4:00 PM

58.55

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

VYNE Therapeutics Inc. (VYNE) stock surged +0.71%, trading at $0.64 on NASDAQ, up from the previous close of $0.64. The stock opened at $0.64, fluctuating between $0.64 and $0.64 in the recent session.

Stock Snapshot

0.6367

Prev. Close

10.69M

Market Cap

0.6382

Day Low

-1.02

P/E Ratio

-0.63

EPS (TTM)

-0.82

Cash Flow per Share

0.64

Open

16.66M

Number of Shares

0.6449

Day High

81.75%

Free Float in %

2.86

Book Value

104.55K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 30, 2026	0.62	0.65	0.62	0.64	37.56K
Apr 29, 2026	0.63	0.65	0.63	0.64	28.33K
Apr 28, 2026	0.64	0.65	0.62	0.64	110.82K
Apr 27, 2026	0.65	0.65	0.64	0.64	26.68K
Apr 23, 2026	0.65	0.65	0.64	0.64	32.87K
Apr 22, 2026	0.63	0.65	0.63	0.65	45.04K
Apr 21, 2026	0.63	0.65	0.63	0.64	148.47K
Apr 20, 2026	0.61	0.64	0.61	0.63	441.01K
Apr 17, 2026	0.62	0.63	0.61	0.61	182.62K
Apr 16, 2026	0.61	0.63	0.61	0.62	85.28K
Apr 14, 2026	0.61	0.63	0.61	0.62	91.34K
Apr 13, 2026	0.61	0.62	0.61	0.62	41.93K
Apr 10, 2026	0.61	0.61	0.61	0.61	101.04K
Apr 09, 2026	0.62	0.62	0.60	0.61	38.43K
Apr 08, 2026	0.59	0.63	0.59	0.61	95.43K
Apr 07, 2026	0.60	0.62	0.59	0.59	46.74K
Apr 06, 2026	0.61	0.62	0.60	0.60	170.66K
Apr 02, 2026	0.61	0.61	0.59	0.60	117.84K
Apr 01, 2026	0.60	0.62	0.59	0.61	120.61K
Mar 31, 2026	0.58	0.61	0.58	0.60	148.8K

Contact Details

Bridgewater, NJ 08807

United States

https://www.vynetherapeutics.com 800 775 7936

About Company

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Stock Peers

ARGX

5.7+0.73%

argenx SE$781.72 REGN

20.7+3.02%

Regeneron Pharmaceuticals, Inc.$707.06 UTHR

0.28+0.05%

United Therapeutics Corporation$571.35 MDGL

-1.19-0.23%

Madrigal Pharmaceuticals, Inc.$517.39 VRTX

4.14+0.98%

Vertex Pharmaceuticals Incorporated$427.38 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-4.36-1.35%

Praxis Precision Medicines, Inc.$318.83 ALNY

8.3+2.76%

Alnylam Pharmaceuticals, Inc.$309.49 KRYS

2.31+0.89%

Krystal Biotech, Inc.$262.26 LGND

4.59+2.04%

Ligand Pharmaceuticals Incorporated$229.45

Frequently Asked Questions

What is the current VYNE Therapeutics Inc. (VYNE) stock price?

VYNE Therapeutics Inc. (NASDAQ: VYNE) stock price is $0.64 in the last trading session. During the trading session, VYNE stock reached the peak price of $0.64 while $0.64 was the lowest point it dropped to. The percentage change in VYNE stock occurred in the recent session was 0.71% while the dollar amount for the price change in VYNE stock was $0.00.

VYNE's industry and sector of operation?

The NASDAQ listed VYNE is part of Biotechnology industry that operates in the broader Healthcare sector. VYNE Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of VYNE?

Dr. Iain A. Stuart Ph.D.
Chief Scientific Officer
Mr. David Schuz
Senior Vice President of Intellectual Property
Mr. Tyler Zeronda
Chief Financial Officer & Treasurer
Dr. Darrell S. Rigel M.S., M.D., MS
Consultant
Ms. Mutya Harsch J.D.
Gen. Counsel, Chief Legal Officer & Company Sec.
Dr. Russell Elliott D.Phil.
Senior Vice President of Pharmaceutical Devel.
Mr. David T. Domzalski
Chief Executive Officer, Pres & Director

How VYNE did perform over past 52-week?

VYNE's closing price is 126.58% higher than its 52-week low of $0.28 where as its distance from 52-week high of $1.96 is -67.52%.

How many employees does VYNE have?

Number of VYNE employees currently stands at 13.

Link for VYNE official website?

Official Website of VYNE is: https://www.vynetherapeutics.com

How do I contact VYNE?

VYNE could be contacted at phone 800 775 7936 and can also be accessed through its website. VYNE operates from 520 U.S. Highway 22, Bridgewater, NJ 08807, United States.

How many shares of VYNE are traded daily?

VYNE stock volume for the day was 104.55K shares. The average number of VYNE shares traded daily for last 3 months was 218K.

What is the market cap of VYNE currently?

The market value of VYNE currently stands at $10.69M with its latest stock price at $0.64 and 16.66M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	13
Beta	2.03
Sales or Revenue	$424.00K
5Y Sales Change%	-0.999%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	13
Beta	2.03
Sales or Revenue	$424.00K
5Y Sales Change%	-0.999%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

VYNE Company Profile and Key Details

VYNE Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics